The problem with AFP as a reliable HCC biomarker is that HCC is positive for the protein in only 60%-80% of cases, and false positives make it difficult to distinguish early stage HCC from other disorders, such as acute hepatitis and cirrhosis, as well as embryonic tumors and certain gastrointestinal tumors. This evidence concerns the gene AFP and embryonal neoplasm.